Pharmacometabolomics: Implications for clinical pharmacology and systems pharmacology

Rima Kaddurah-Daouk, R. M. Weinshilboum

Research output: Contribution to journalArticle

109 Scopus citations

Abstract

Metabolomics, the study of metabolism at an "omic" level, has the potential to transform our understanding of mechanisms of drug action and the molecular basis for variation in drug response. It is now possible to define metabolic signatures of drug exposure that can identify pathways involved in both drug efficacy and adverse drug reactions. In addition, the "metabotype," the metabolic "signature" of a patient, is a unique identity that contains information about drug response and disease heterogeneity. The application of metabolomics for the study of drug effects and variation in drug response is creating "pharmacometabolomics," a discipline that will contribute to personalized drug therapy and will complement pharmacogenomics by capturing environmental and microbiome-level influences on response to drug therapy. This field has the potential to transform pharmacology and clinical pharmacology in significant ways and will contribute to efforts for personalized therapy. This overview highlights developments in the new discipline of pharmacometabolomics.

Original languageEnglish (US)
Pages (from-to)154-167
Number of pages14
JournalClinical pharmacology and therapeutics
Volume95
Issue number2
DOIs
StatePublished - Feb 1 2014

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Pharmacometabolomics: Implications for clinical pharmacology and systems pharmacology'. Together they form a unique fingerprint.

  • Cite this